Maravai LifeSciences Holdings, Inc.
$6.98-$0.21 (-2.9%)
Last close · Data as of Nov 20, 2026
- Market cap
- $1.8B
- P/E
- -14.1x
- EV / EBITDA
- -13.5x
- Revenue
- $185.7M
- Net margin
- -70.4%
- ROCE
- -17.7%
Price chart
Technical chartScreen technicals →+104.1% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -3.1%
- 3M
- -15.8%
- 6M
- +57.6%
- 1Y
- +104.1%
- 5Y
- -81.4%
52-week range
Day change -$0.21 (-2.9%) from $7.19 to $6.98 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in MRVI, bought on each weekday since 2021.
News & filings
What Maravai LifeSciences Holdings filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 131 million US dollars in fiscal 2025.
Strengths (1)
- The price is 26.3% above its 200-day average, and the 50-day average is above the 200-day.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.
Read moreShow less
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and emerging biopharmaceutical and life sciences research companies; and academic research institutions and diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Shares outstanding
- 145.3M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $1.8B
- P/E
- -14.1x
- P/B
- 8.7x
- EV / EBITDA
- -13.5x
- EV / Sales
- 10.7x
- P/S
- 9.9x
- 52-week high
- $9.00
- 52-week low
- $2.83
Profitability
- Operating margin
- -69.2%
- Net margin
- -70.4%
- EBITDA margin
- -79.4%
- ROE
- -61.6%
- ROCE
- -17.7%
- ROIC
- -31.6%
- ROA
- -17.0%
- Asset turnover
- 0.24
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $185.7M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -28.3%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- -40.5%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -9.7%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$70.7M
Solvency
- Current ratio
- 6.60
- Debt / Equity
- 1.72
- Debt / Assets
- 0.47
- CFO / Net profit
- 0.44
- Cash / Market cap
- 11.8%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $185.7M |
| Cost of revenue | $151.8M |
| Gross profit | $34.0M |
| Operating expenses | $162.5M |
| Research and development | $17.4M |
| Selling, general and administrative | $145.1M |
| Operating income | -$128.5M |
| Interest and other | -$106.4M |
| Pretax income | -$235.0M |
| Tax and other | -$104.2M |
| Net income | -$130.8M |
Revenue and net profit
Revenue fell 28.3% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $883.0M | $220.2M |
| FY2023 | $288.9M | -$119.0M |
| FY2024 | $259.2M | -$144.8M |
| FY2025 | $185.7M | -$130.8M |
Cash flows
FY2025: -$57.6M from operations, -$70.7M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $536.0M | $518.9M |
| FY2023 | $126.2M | $60.7M |
| FY2024 | $7.5M | -$22.2M |
| FY2025 | -$57.6M | -$70.7M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $185.7M-28.3%1Y
- EBITDA
- -$147.5M
- Net profit
- -$130.8M
- Cash from operations
- -$57.6M-871.2%1Y
- Free cash flow
- -$70.7M
- Revenue CAGR, 3Y
- -40.5%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $185.7M | -$147.5M | -$130.8M | -$70.7M | -61.6% | -28.3% | -9.7% |
Monthly returns
Month-by-month returns of MRVI across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $770.6M |
| Current assets | $296.3M |
| Non-current assets | $474.3M |
| Liabilities | $397.9M |
| Current liabilities | $44.9M |
| Non-current liabilities | $352.9M |
| Equity | $372.7M |
| Paid-in capital | $199.2M |
| Retained earnings | $10.1M |
| Minority interest | $160.3M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; MRVI highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Maravai LifeSciences Holdings, Inc.MRVIthis company | $1.8B | -14.1x | 8.7x | -61.6% | -13.5x |
| Astrana Health, Inc.ASTH | $1.9B | 83.5x | 2.4x | 2.9% | 18.7x |
| Stoke Therapeutics, Inc.STOK | $1.9B | -272.5x | 5.3x | -2.0% | -95.4x |
| Pulse Biosciences, Inc.PLSE | $1.9B | -25.6x | 23.1x | -90.2% | -23.6x |
| Zymeworks Inc.ZYME | $1.8B | -22.8x | 6.9x | -30.2% | -22.4x |
| Pediatrix Medical Group, Inc.MD | $1.8B | 11.1x | 2.1x | 19.1% | 7.6x |
| Viridian Therapeutics, Inc.VRDN | $1.8B | -5.3x | 3.1x | -58.1% | -4.9x |
| Vericel CorporationVCEL | $1.8B | 110.3x | 5.1x | 4.7% | 60.3x |
| ANI Pharmaceuticals, Inc.ANIP | $1.8B | 23.0x | 3.3x | 14.5% | 10.3x |
| Peer median | — | 2.9x | 4.2x | 0.5% | 1.3x |
Year-to-date ROI
MRVI since 1 January, against earlier years.
Historical volatility
MRVI's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 64.1% |
| FY2023 | -9.9% |
| FY2024 | -28.0% |
| FY2025 | -69.2% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $185.7M |
| Cost of revenueCost Of Revenue | $151.8M |
| Gross profitGross Profit | $34.0M |
| Operating expensesOperating Expense | $162.5M |
| Research and developmentResearch And Development | $17.4M |
| Selling, general and administrativeSelling General And Administration | $145.1M |
| Total expensesTotal Expenses | $314.3M |
| Operating incomeOperating Income | -$128.5M |
| Interest and other | |
| Pretax incomePretax Income | -$235.0M |
| TaxTax Provision | -$4.2M |
| Net incomeNet Income | -$130.8M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $770.6M |
| Current assetsCurrent Assets | $296.3M |
| Non-current assetsTotal Non Current Assets | $474.3M |
| LiabilitiesTotal Liabilities Net Minority Interest | $397.9M |
| Current liabilitiesCurrent Liabilities | $44.9M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $352.9M |
| EquityTotal Equity Gross Minority Interest | $372.7M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | -$57.6M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$57.6M |
| Net income, continuing operationsNet Income From Continuing Operations | -$230.8M |
| Depreciation and amortisationDepreciation And Amortization | $60.5M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $60.5M |
| Depreciation | $32.5M |
| Amortization cash flowAmortization Cash Flow | $27.9M |
| Amortization of intangiblesAmortization Of Intangibles | $27.9M |
| Stock-based compensationStock Based Compensation | $30.2M |
| Deferred taxDeferred Tax | $4.1M |
| Deferred income taxDeferred Income Tax | $4.1M |
| Operating gains and lossesOperating Gains Losses | — |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | — |
| Gain loss on sale of businessGain Loss On Sale Of Business | — |
| Asset impairmentAsset Impairment Charge | $84.6M |
| Change in working capitalChange In Working Capital | -$8.0M |
| Other non-cash itemsOther Non Cash Items | $1.9M |
| Investing cash flowInvesting Cash Flow | -$31.4M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$31.4M |
| Capital expenditureCapital Expenditure | -$13.2M |
| Purchase of PP&EPurchase Of PPE | -$13.2M |
| Sale of PP&ESale Of PPE | $730.0k |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$12.4M |
| AcquisitionsPurchase Of Business | -$19.0M |
| DisposalsSale Of Business | — |
| Net acquisitions and disposalsNet Business Purchase And Sale | -$19.0M |
| Purchase of intangiblesPurchase Of Intangibles | — |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | — |
| Other investing changesNet Other Investing Changes | — |
| Financing cash flowFinancing Cash Flow | -$16.5M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$16.5M |
| Debt issuedIssuance Of Debt | — |
| Debt repaidRepayment Of Debt | -$5.4M |
| Net debt issuedNet Issuance Payments Of Debt | -$5.4M |
| Long-term debt issuedLong Term Debt Issuance | — |
| Long-term debt repaidLong Term Debt Payments | -$5.4M |
| Net long-term debt issuedNet Long Term Debt Issuance | -$5.4M |
| Shares issuedIssuance Of Capital Stock | — |
| Common stock issuedCommon Stock Issuance | — |
| Net common stock issuedNet Common Stock Issuance | — |
| Common stock repurchasedCommon Stock Payments | — |
| Share buybacksRepurchase Of Capital Stock | — |
| Stock options exercisedProceeds From Stock Option Exercised | — |
| Other financing chargesNet Other Financing Charges | -$11.1M |
| Change in cashChanges In Cash | -$105.5M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | -3.0% |
| Cash at the start of the yearBeginning Cash Position | $322.4M |
| Cash at the end of the yearEnd Cash Position | $216.9M |
| Free cash flowFree Cash Flow | -$70.7M |
| Supplemental |
Learn while you research
Academy chapters picked for Maravai LifeSciences Holdings, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Leverage RatiosDebt/Equity of 1.72 is elevated, understand what that means for solvency.6 min read
- 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read